What does Industry 6.0 mean for pharmaceutical manufacturers?

There is also a strong business case to adopt autonomous technologies. Solutions such as generative AI (genAI) could potentially generate upwards of $60 billion in economic value per year.²

This will pave the way for an increasingly digital and automated landscape in pharmaceutical processing, bringing the possibility of Industry 6.0 closer to the horizon.

Before diving into what Industry 6.0 means for pharma manufacturers, it is important to establish what this concept could look like by understanding its predecessors: Industries 4.0 and 5.0.

It is well documented that Industry 4.0 has focused on a more connected and streamlined use of AI in manufacturing and operations processes.³

By contrast, Industry 5.0 has been more about balancing the human role and what technology can do to solve ongoing societal and sustainable challenges.⁴